Predictors for Post-treatment Biopsy Outcomes after Prostate Stereotactic Body Radiotherapy
Stereotactic body radiotherapy (SBRT) is a well-recognized treatment option for low- and intermediate-risk prostate cancer. Five-year prostate-specific antigen (PSA) relapse-free survival rates of approximately 90% have been reported for patients with low-risk and intermediate-risk disease when delivering SBRT prescription dose levels ranging from 34 –50 Gy [1-7]. Recent reports of prospective randomized trials comparing SBRT to moderate hypo-fractionated radiotherapy have demonstrated comparable disease-related outcomes for patients treated for low-risk and intermediate-risk prostate cancer [8,9].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Michael J Zelefsky, Debra A. Goldman, Margaret Hopkins, Attapol Pinitpatcharalert, Sean McBride, Daniel Gorovets, Behfar Ehdaie, Samson W. Fine, Victor E. Reuter, Neelam Tyagi, Laura Happersett, Achiraya Teyateeti, Zhigang Zhang, Marisa A. Kollmeier Tags: Original Article Source Type: research